Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

A 74-year-old man, diagnosed with advanced kidney cancer and facing an 80% damaged kidney, opted for natural treatment at ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

Dutch-Turkish rapper Yukkie B, born Yuksel Ozince, died Sunday at the age of 56 from kidney cancer, his former partner ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

The Kidney Cancer Association (KCA), a global community dedicated to serving and empowering patients and caregivers and ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination ...